Clinical observation of docetaxel combined with S-1 in treatment of anthracycline-resistant TNBC
- VernacularTitle:多西紫杉醇联合替吉奥对蒽环类耐药TNBC患者的临床疗效观察
- Author:
Wanli YE
;
Jianfang WANG
;
Hongjian YANG
- Publication Type:Journal Article
- Keywords:
Docetaxel;
S-1;
anthracycline-resistant;
triple negative breast cancer
- From:
Chinese Journal of Biochemical Pharmaceutics
2014;(3):116-118
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe and analyze the clinical efficacy of docetaxel and S-1 in treatment of anthracycline-resistant triple-negtive breast cancer(TNBC).Methods 64 cases with TNBC admitted in People' Hospital of Shaoxing City from June 2009 to June 2011were selected as research object.The clinical data of these cases were analyzed retrospectively.Anthracycline had been used to treat the cases, but with no effect or recurrence.Then docetaxel combined with S-1 was applied to the cases.Clinical efficacy and adverse reactions of the chemotherapy were observed and analyzed. Results After treatment,the efficiency of 64 cases was 54.69%,and the disease control rate was 79.69%.During the treatment,the main adverse reactions were gastrointestinal reactions and bone marrow suppression,without death,and patients could tolerate the adverse event.Follow-up results showed that the median time of progression was 10.5 months.After two years,progression-free survival rate was 0.Conclusion Docetaxel combined with S-1 has good clinical efficacy for anthracycline-resistant triple-negtive breast cancer,with relatively mild side effects,which may be an ideal adjuvant chemotherapy method.
